Erratum: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy (Support Care in Cancer (2005) 13 (85-96) DOI: http://dx.doi.org/10.1007/s00520-004-0699-x);Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

Supportive Care in Cancer

Volumn 13, Issue 2, 2005, Pages 85-96

  Kris, Mark G ^a   Hesketh, Paul J ^b   Herrstedt, Jorn ^c   Rittenberg, Cynthia ^d   Einhorn, Lawrence H ^e   Grunberg, Steven ^f   Koeller, Jim ^g   Olver, Ian ^h   Borjeson, Sussanne ⁱ   Ballatori, Enzo ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mental Health Services CPH   (Denmark)

^d Rittenberg Oncology Consulting   (United States)

^e WALTHER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

ⁱ LINKÖPING UNIVERSITY   (Sweden)

^j Azienda Opedaliera   (Italy)

more..

Author keywords

Aprepitant; Chemotherapy; Cisplatin; Dexamethasone; Serotonin antagonists

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CORTICOTROPIN; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; EZLOPITANT; GRANISETRON; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NITROSOUREA DERIVATIVE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 20244390153     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0833-4     Document Type: Erratum

References (81)

1. Aapro E, Selak M, Lichinitser D, Santini A, Macciocchi A, Klinik A, Blokhin NN (2003) Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a Phase III trial. Proc ASCO 22:726
2. Andrews PLR, Davis CJ (1993) The mechanism of emesis induced by anticancer therapies. In: Andrews PLR and G.J. Sanger (eds) Emesis in anticancer therapy mechanisms and treatment. Chapman & Hall, London, pp 14-17
3. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple- dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975
4. Blum RA, Majumdar A, McCrea J, et al (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407-1419
5. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767
6. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300
7. Chevalier B (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26:S33-S36
8. Cocquyt V, VanBelle S, Reinhardt RR, Decramer MLA, O'Brien M, Schellens JHM, Borms M, Verbeke L, VanAelst F, DeSmet M, Carides AD, Eldridge K, Gertz BJ (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754-030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835-842
9. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer ME, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oraf NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105-4111
10. de Wit R, Herrstedt J, Rapoport B, et al (2004) The oral NK1 antagonist aprepitant given with standard antiemetics provided protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. A combined analysis of 2 randomized, placebo-controlled trials. Eur J Cancer 40:403-410
11. 3 antagonist prophylaxis is not maintained. J Clin Oncol 14:644-651
12. de Wit R, van den Berg H, Burghouts J, et al (1998) Initial high antiemetic efficacy of ganisetron with dexamethasone is not maintained over repeated doses. Br J Cancer 77:1487-1491
13. DeMulder PH, Seynaeve C, Vermorken JB, van LPA, Mols JS, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834-840
14. 3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482
15. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15:330-337
16. Evidence-Based Medicine WG (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 268:420-425
17. Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A:35-38
18. Gandara DR, Roila F, Warr DG, Edelman MJ, Perez EA, Gralla RJ (1998) Consensus proposal for 5-HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Supp Care Cancer 6:237-243
19. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind placebo-controlled, comparative study. Ann Oncol 6:661-666
20. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
21. Gralla RJ, Tyson LB, Kris MG, Clark RA (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 71:289-301
22. Gralla RJ, Popovic W, Strup J, Culleton V, Preston A, Friedman C (1997) Can an oral antiemetic regimen be as effective as intravenous treatment against cisplatin: results of a 1054 patient randomized study of oral granisetron versus IV ondansetron. Proc ASCO 16:52b
23. Gridelli C, Ianniello GP, Ambrosini G, et al (1997) Multicentre, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol 10:395-400
24. Grunberg SM, Stevenson LL, Russell CA, McDermed JE (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137-1141
25. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
26. Grunberg SM, Lane M, Lester EP, Sridhar KS, Mortimer J, Murphy W, Sanderson PE (1993) Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268-272
27. Grunberg SM, Hesketh PJ, Carides AD, et al (2003) Relationships between the incidence and control of cisplatin-induced acute vomiting and delayed vomiting: Analysis of pooled data from two phase III studies of the NK-1 antagonist aprepitant. Proc Am Soc Clin Oncol 22:2931a
28. Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728
29. Heron JF (1995) Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22:24-30
30. Herrstedt J (1996) New perspectives in antiemetic treatment. Support Care Cancer 4:416-419
31. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705
32. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of anti-emetic agents. J Natl Cancer Inst 83:613-620
33. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized phase ii study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 17:338-343
34. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
35. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249
36. IGAR (1994) Italian Group for Anti-emetic Research: Cisplatin-induced delayed emesis: Prognostic factors during three subsequent cycles. Ann Oncol 5:585-589
37. IGAR (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810
38. IGAR (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130
39. IGAR (1998) Double-Blind, Dose-Finding Study of Four Intravenous Doses of Dexamethasone in the Prevention of Cisplatin-Induced Acute Emesis. J Clin Oncol 16:2937-2942
40. IGAR (1999) A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. Anticancer Drugs 5:465-470
41. Kris MG, Gralla RJ, Clark RA, Tyson LB, OConnell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384
42. Kris MG, Gralla RJ, Clark RA, Tyson LB (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an anti-emetic in patients receiving anticancer chemotherapy. J Clin Oncol 6:659-662
43. Kris MG, Gralla RJ, Clark RA, Tyson LB (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42-46
44. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114
45. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
46. Kris MG, Roila F, de Mulder PHM, Marty M (1998) Delayed emesis following anticancer chemotherapy. Support Care Cancer 6:228-232
47. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174-1178
48. Louvet C, Lorange A, Letendre F, et al (1991) Acute and delayed emesis after cisplatin-based regimen: Description and prevention. Oncology 48:392-396
49. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade LE, Paule B, Paes D, Bons J (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
50. Marty M, Kleisbauer J-p, Fournet P, Vergnenegro A, Carics P, Loria-Kanza Y, Simonetta C, Bruijn KM (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anti-Cancer Drugs 6:15-21
51. Matsui K, Fukuoka M, Takada M, Kunsunoki Y, Yana T, Tamura K (1996) Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 73:217-221
52. Milano S, Blower P, Romain D, Grelot L (1995) The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J Pharmacol Exp Ther 274:951-961
53. Moreno I, Rosell R, Abad A (1992) Comparison of three protracted anti-emetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 28A:1344-1347
54. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204-2210
55. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248
56. Navari RMI, Hesketh PJr (1999) Use of Placebos in Delayed-Emesis Studies (letter). J Clin Oncol 17:338-343
57. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, Huffman DH, Gould JR, Carron G, Ossi M, Anderson EM (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408-2416
58. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:190-195
59. Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16:771-778
60. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945-952
61. Passalacqua R, Cocconi G, Bella M, Monici L, Michiara M, Bandini N, Bacchi M (1992) Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 3:481-485
62. Passalacqua R, Cocconi G, Caminiti C, Silingardi V, Bella MA, Bichisao E, Michiara M, Malavasi V, Donati D, DiCostanzo F, Rocca A, DiSarra S, Scaglione F, Fraschini F (1997) Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer. J Clin Oncol 15:2467-2473
63. Perez EA (1995) Review of the preclinical pharmacology and comparative efficacy of 5-hydroxyoyptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 13:1036-1043
64. Perez EA, Hesketh PJ, Gandara DR (1991) Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol 18:73-80
65. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
66. Riviere A, on behalf of the Granisetron Study Group (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971
67. Roila F, Boschetti E, Tonato M (1991) Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14:238-242
68. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675-678
69. Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88-95
70. Rudd JA, Jordan CC, Naylor RJ (1994) Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 262:R1-R2
71. Ruff P, Paska W, Goedhals L, Pouiliart P, Riviere A, on behalf of the Granisetron Study Group, Vorolieof D, Bloch, Jones A, Martin L, Brunet R, Butcher, Forster J, McQuade B, on behalf of the Ondansetron and Granisetron Emesis Study Group (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 51:113-118
72. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Pacs D, de Mulder PHM, on behalf of the Ondansetron Study Group (1992) Comparison of the antiemetic efficacy of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicenter, double-blind, randomized, parallel group study. Br J Cancer 66:192-197
73. Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tamura T, Fujiwara Y (1989) Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 19:40-44
74. Smyth J (1992) Delayed emesis after high-dose cisplatin-the residual problem. In: Proceedings of the Satellite Symposium to the XVII Congress of the European Society for Medical Oncology, Lyon, pp. 24-26
75. Soukop J, on behalf of the Granisetron Study Group (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177-183
76. Soukop M, McQuade B, Hunter E, et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304
77. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ (1994) Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin receptor antagonist CP-99,994. Neuropharmacology 33:259-260
78. Thant M, Pendergras K, Harman G, Modiano M, Martin L, DuBois D, Cramer M, Hahne W (1996) Double-blind, randomized study of the dose-response relationship across five single doses of IV dolasetron mesylate (DM) for prevention of acute nausea and vomiting (ANC) after cisplatin chemotherapy (CCT). Proc ASCO 15:533
79. Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37:2398-2404
80. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer MLA, Rivier A, Thant M, Brestan E, Bui B, Eldridge K, DeSmet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758-298 and MK-869. Cancer 94(11):3032-3041
81. Van Belle S-P, Stamatakis L, Bleiberg H, Cocquyt FJ, Michel J, de Bruijn KM (1994) Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 5:821-825